TY  - JOUR
AU  - Grafetstätter, Mirja
AU  - Hüsing, Anika
AU  - González Maldonado, Sandra
AU  - Sookthai, Disorn
AU  - Johnson, Theron S
AU  - Pletsch-Borba, Laura
AU  - Katzke, Verena
AU  - Hoffmeister, Michael
AU  - Bugert, Peter
AU  - Kaaks, Rudolf
AU  - Kuehn, Tilman
TI  - Plasma Fibrinogen and sP-Selectin are associated with the risk of lung cancer in a prospective study.
JO  - Cancer epidemiology, biomarkers & prevention
VL  - 28
IS  - 7
SN  - 1538-7755
CY  - Philadelphia, Pa.
PB  - AACR
M1  - DKFZ-2019-01314
SP  - 1221-1227
PY  - 2019
AB  - While enhanced platelet activation and a procoagulant state may drive lung cancer progression and metastases, less is known about their role in earlier phases of cancer development. Thus, we evaluated whether pre-diagnostic biomarkers of platelet activation and coagulation are related to the risk of lung cancer in the prospective EPIC-Heidelberg Study using a case-cohort design.Levels of fibrinogen, soluble glycoprotein (sGP) IIb/IIIa, soluble P-selectin (sP-selectin), soluble thrombomodulin (sTM), and thrombopoietin (TPO) were measured in baseline plasma samples of a random subcohort (n=2,480) and incident cases of lung cancer (n=190). Multivariable-adjusted Cox proportional hazards regression analyses were used to obtain Hazard Ratios (HRs) of lung cancer across quartiles of biomarker levels.Fibrinogen (HR highest vs. lowest quartile: 1.91 [95 
LB  - PUB:(DE-HGF)16
C6  - pmid:31015200
DO  - DOI:10.1158/1055-9965.EPI-18-1285
UR  - https://inrepo02.dkfz.de/record/143745
ER  -